New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.What Happened?On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercorti ...

NEW YORK, Jan. 14, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registratio ...

NEW YORK, Jan. 14, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus issu ...

Core Viewpoint - A class action securities lawsuit has been filed against SLM Corporation, alleging securities fraud that affected investors between July 25, 2025, and August 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that SLM Corporation experienced a significant increase in early-stage delinquencies, which was not disclosed to investors [2]. - It is alleged that the defendants overstated the effectiveness of SLM's loss mitigation and loan modification programs, misleading investors about the company's stability [2]. - The public statements made by the defendants created a materially false and misleading impression regarding SLM's business operations and future prospects [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until February 17, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on treatments for obesity and metabolic diseases [2]. Group 3: Allegations - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Group 4: Stock Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Performance Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partnerships for development [4]. Allegations of Securities Fraud - The lawsuit claims that CoreWeave misrepresented its ability to meet customer demand and concealed construction delays at its data centers, despite assurances of robust demand and competitive strengths [5]. Stock Performance and Impact - On October 30, 2025, CoreWeave's stock dropped by $8.87 (over 6%) after the termination of a merger agreement with Core Scientific due to insufficient shareholder votes [6]. - Following a revenue guidance reduction on November 10, 2025, the stock fell by $17.22 (over 16%) due to delays from a third-party data center developer [7]. - A report on December 15, 2025, regarding further delays in a major data center project led to an additional drop of $2.85 (over 3%) in stock price [8].

Core Points - The CoreWeave class action lawsuit involves allegations against CoreWeave, Inc. and its executives for violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave overstated its ability to meet customer demand and failed to disclose significant risks associated with its reliance on a single third-party data center supplier [3] - CoreWeave's stock price experienced significant declines following announcements related to merger agreements and lowered revenue guidance, with a drop of over 6% after the termination of the merger with Core Scientific and a further decline of more than 16% after revenue guidance was lowered due to delays [4][5] Allegations and Events - CoreWeave announced a deal worth up to $11.9 billion with OpenAI for AI infrastructure shortly before its IPO [2] - The lawsuit alleges that on October 30, 2025, Core Scientific did not receive enough shareholder votes to approve its merger with CoreWeave, leading to the termination of the agreement [4] - On November 10, 2025, CoreWeave lowered its revenue guidance due to delays from a third-party data center developer, which was later revealed to involve multiple data centers owned by the same provider [5] - A December 15, 2025 article from The Wall Street Journal reported that delays in data center delivery were more severe than previously acknowledged, causing an additional drop of 3.4% in CoreWeave's stock price [6] Legal Process - Investors who purchased CoreWeave securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7] - The lead plaintiff has the authority to select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [8]

Core Viewpoint - The Smartsheet Inc. class action lawsuit has been initiated due to alleged violations related to the acquisition by Blackstone Inc., Vista Equity Partners Management, LLC, and the Abu Dhabi Investment Authority, with shareholders having until February 24, 2026, to seek lead plaintiff status [1][5]. Group 1: Class Action Details - Shareholders who held Smartsheet securities as of October 25, 2024, are eligible to participate in the class action lawsuit [1][2]. - The lawsuit alleges that a misleading Schedule 14A Proxy statement was issued, which led to shareholders approving the merger at an unfair price of $56.50 per share [3][4]. - The complaint claims that the Proxy failed to disclose important financial metrics, such as the Annual Recurring Revenue (ARR), which was touted in press releases and earnings calls as a key indicator of Smartsheet's financial performance [4]. Group 2: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who held Smartsheet securities as of the record date to seek lead plaintiff status, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 3: Company Background - Smartsheet is an enterprise software company that provides software-as-a-service (SaaS) work management solutions, tracking its Annual Recurring Revenue (ARR) as a key performance metric [2].

Core Viewpoint - A class action lawsuit has been filed against Smart Digital Group Limited (SDM) for allegedly misleading investors during a specific class period, leading to significant financial losses due to market manipulation and fraudulent activities [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case name Dixit v Smart Digital Group Limited, et.al, and covers individuals who purchased SDM securities between May 5, 2025, and September 26, 2025 [1]. - Investors have until March 16, 2026, to apply to serve as lead plaintiff in this action [2]. Group 2: Allegations Against the Company - Defendants are accused of making materially false and misleading statements and failing to disclose adverse facts about SDM's business and operations [3]. - Specific allegations include: 1. Involvement in a market manipulation scheme using social media misinformation [3]. 2. Use of offshore accounts for coordinated share dumping during a price inflation campaign [3]. 3. Omission of risks related to fraudulent trading and market manipulation in public statements [3]. 4. Unique risk of trading suspension by the SEC and NASDAQ due to these activities [3]. 5. Misleading positive statements about the company's business and prospects [3]. Group 3: Stock Price Impact - On September 26, 2025, SDM's stock price plummeted by 86.4%, closing at $1.85 per share, following a trading halt by NASDAQ due to high volatility [4]. - The SEC suspended trading in SDM securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [5]. - Following the SEC suspension, NASDAQ also halted trading in SDM securities pending further information [5].